Sino Biopharmaceutical Limited

DB:SMZ1 Stock Report

Market Cap: €6.8b

Sino Biopharmaceutical Valuation

Is SMZ1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SMZ1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€1.29
Fair Value
70.9% undervalued intrinsic discount
23
Number of Analysts

Below Fair Value: SMZ1 (€0.38) is trading below our estimate of fair value (€1.29)

Significantly Below Fair Value: SMZ1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SMZ1?

Key metric: As SMZ1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SMZ1. This is calculated by dividing SMZ1's market cap by their current earnings.
What is SMZ1's PE Ratio?
PE Ratio24x
EarningsCN¥2.14b
Market CapCN¥51.50b

Price to Earnings Ratio vs Peers

How does SMZ1's PE Ratio compare to its peers?

The above table shows the PE ratio for SMZ1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.8x
DMP Dermapharm Holding
23.2x17.3%€2.1b
MRK Merck KGaA
21.8x10.2%€58.7b
PSG PharmaSGP Holding
18.2x14.1%€342.9m
1SXP SCHOTT Pharma KGaA
23.9x13.9%€3.6b
SMZ1 Sino Biopharmaceutical
24x12.6%€54.9b

Price-To-Earnings vs Peers: SMZ1 is expensive based on its Price-To-Earnings Ratio (24x) compared to the peer average (21.8x).

Price to Earnings Ratio vs Industry

How does SMZ1's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SMZ1 24.0xIndustry Avg. 22.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SMZ1 is expensive based on its Price-To-Earnings Ratio (24x) compared to the European Pharmaceuticals industry average (22.1x).

Price to Earnings Ratio vs Fair Ratio

What is SMZ1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SMZ1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24x
Fair PE Ratio17.6x

Price-To-Earnings vs Fair Ratio: SMZ1 is expensive based on its Price-To-Earnings Ratio (24x) compared to the estimated Fair Price-To-Earnings Ratio (17.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SMZ1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.38
€0.56
+47.8%
20.3%€0.85€0.37n/a23
Feb ’26€0.36
€0.55
+51.3%
20.3%€0.84€0.37n/a23
Jan ’26€0.40
€0.55
+39.9%
20.4%€0.85€0.37n/a22
Dec ’25€0.41
€0.54
+32.1%
20.7%€0.84€0.35n/a23
Nov ’25€0.43
€0.54
+24.3%
20.6%€0.83€0.35n/a23
Oct ’25€0.42
€0.54
+28.0%
22.8%€0.82€0.36n/a23
Sep ’25€0.37
€0.53
+42.6%
23.1%€0.81€0.35n/a23
Aug ’25€0.32
€0.54
+67.2%
29.7%€1.08€0.35n/a23
Jul ’25€0.31
€0.55
+76.4%
29.2%€1.08€0.36n/a23
Jun ’25€0.33
€0.54
+62.5%
29.4%€1.08€0.35n/a23
May ’25€0.32
€0.56
+75.3%
28.9%€1.09€0.36n/a22
Apr ’25€0.35
€0.56
+58.3%
30.0%€1.09€0.36n/a21
Mar ’25€0.36
€0.60
+65.6%
32.1%€1.08€0.36n/a21
Feb ’25€0.34
€0.60
+74.8%
31.7%€1.10€0.36€0.3622
Jan ’25€0.40
€0.66
+65.0%
43.1%€1.66€0.35€0.4024
Dec ’24€0.43
€0.65
+50.8%
42.3%€1.66€0.35€0.4125
Nov ’24€0.36
€0.67
+82.6%
42.4%€1.69€0.36€0.4325
Oct ’24€0.33
€0.68
+104.2%
39.4%€1.69€0.36€0.4226
Sep ’24€0.36
€0.69
+91.4%
37.1%€1.67€0.36€0.3727
Aug ’24€0.44
€0.74
+68.5%
37.2%€1.66€0.43€0.3224
Jul ’24€0.43
€0.80
+86.6%
35.1%€1.65€0.44€0.3122
Jun ’24€0.45
€0.83
+86.6%
34.2%€1.66€0.46€0.3322
May ’24€0.50
€0.83
+67.0%
33.8%€1.65€0.46€0.3222
Apr ’24€0.52
€0.87
+69.8%
31.9%€1.70€0.47€0.3522
Mar ’24€0.50
€0.89
+78.5%
31.4%€1.72€0.50€0.3622
Feb ’24€0.54
€0.90
+64.6%
31.6%€1.71€0.50€0.3422
Analyst Price Target
Consensus Narrative from 23 Analysts
€0.56
Fair Value
32.5% undervalued intrinsic discount
23
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 01:29
End of Day Share Price 2025/02/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sino Biopharmaceutical Limited is covered by 50 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Justin LiuBNP Paribas Securities (Asia)
Sharon ShiBOCI Research Ltd.